Molecular Therapy Methods & Clinical Development
Scope & Guideline
Pioneering clinical developments in cell therapy.
Introduction
Aims and Scopes
- Gene Therapy Techniques:
The journal emphasizes the development and refinement of gene therapy methodologies, including viral vector design, delivery systems, and genome editing technologies. - Cell Therapy Innovations:
It explores advancements in cell therapies, particularly those involving engineered immune cells, stem cells, and their applications in treating various diseases. - Clinical Development and Trials:
The journal covers the translation of molecular therapies into clinical settings, discussing trial designs, outcomes, and regulatory considerations. - Analytical Techniques:
There is a strong focus on analytical methods for characterizing therapeutic vectors, assessing their efficacy, and understanding their interactions within biological systems. - Safety and Immunogenicity:
Research on the safety profiles of gene and cell therapies, including immune responses and long-term effects, is a critical area of investigation.
Trending and Emerging
- CRISPR and Genome Editing:
There is a significant increase in publications focusing on CRISPR technology and innovative genome editing strategies, highlighting its potential for precise therapeutic applications. - Personalized Medicine Approaches:
Emerging research emphasizes personalized gene therapies tailored to individual genetic profiles, which is crucial for enhancing efficacy and safety in clinical applications. - Novel Vector Development:
The development of new viral vectors and modifications to existing ones, such as engineered AAV capsids for improved tropism, is gaining traction as researchers seek to enhance delivery efficiency. - Combination Therapies:
The trend towards exploring combination therapies that integrate gene therapy with other modalities, such as immune checkpoint inhibitors or small molecule drugs, is becoming more prevalent. - Long-term Safety and Efficacy Studies:
There is an increasing emphasis on long-term studies assessing the safety and durability of therapeutic effects, reflecting a growing concern for the chronic administration of gene therapies.
Declining or Waning
- Traditional Viral Vectors:
Research on conventional viral vectors, such as older AAV serotypes, appears to be declining as newer, more effective vector technologies are developed and adopted. - Non-viral Gene Delivery Systems:
Interest in non-viral methods for gene delivery, while still relevant, has decreased in favor of advancements in viral vector technologies that demonstrate higher efficiency and specificity. - Basic Mechanistic Studies:
There seems to be a waning focus on basic mechanistic studies of gene delivery processes, as the field shifts towards more applied research and clinical outcomes. - Animal Models in Preclinical Studies:
The reliance on traditional animal models for preclinical testing is being challenged by the development of more sophisticated in vitro systems and humanized models. - Regulatory Frameworks:
Discussions around regulatory frameworks for gene therapy appear less frequent as the field matures and more established guidelines are adopted.
Similar Journals
BLOOD CELLS MOLECULES AND DISEASES
Connecting Molecular Biology to Hematologic HealthBLOOD CELLS MOLECULES AND DISEASES is a prominent multidisciplinary journal published by Academic Press Inc., Elsevier Science, specializing in the fields of hematology, molecular biology, and cell biology. With an ISSN of 1079-9796 and an E-ISSN of 1096-0961, this journal serves as a vital resource for researchers, professionals, and students exploring the complex interplay between blood cells and their corresponding molecular pathways in disease states. Spanning topics from cellular mechanisms to therapeutic advancements, BLOOD CELLS MOLECULES AND DISEASES holds a commendable reputation with a 2023 category quartile ranking of Q2 in Hematology and Q3 in several related fields. This journal not only provides a platform for the dissemination of innovative research but also fosters collaboration and knowledge exchange within the scientific community. As it converges from 1995 to 2025, the journal continues to impact the medical and biological sciences significantly, making it an essential tool for advancing our understanding of hematologic diseases.
DRUGS
Connecting Laboratory Insights with Clinical PracticeDRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.
CELL TRANSPLANTATION
Empowering the next generation of transplantation science.CELL TRANSPLANTATION is a premier multidisciplinary journal dedicated to advancing the field of regenerative medicine and transplantation, published by SAGE PUBLICATIONS INC. Since its initiation in 1992 and embracing an open-access model since 2017, the journal aims to disseminate high-quality research that covers both clinical and experimental studies on cell and tissue transplantation. With a notable impact reflected in its 2023 Q2 ranking in Biomedical Engineering and significant standings in Cell Biology and Transplantation, CELL TRANSPLANTATION serves as a vital resource for researchers, practitioners, and students alike. The journal's commitment to fostering innovation is evident in its diverse contributions that address the complexities of tissue engineering, immunology, and regenerative therapies, inviting readers to engage with cutting-edge science that is poised to transform medical practices and improve patient outcomes. The journal's insightful articles and research findings make it a crucial platform for knowledge exchange within the vibrant scientific community.
JOURNAL OF CLINICAL IMMUNOLOGY
Exploring the Dynamics of Immune ResponsesJOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.
MOLECULAR NEUROBIOLOGY
Bridging Basic Science and Clinical InnovationWelcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.
CYTOTHERAPY
Advancing the Future of Cell Therapy.CYTOTHERAPY is a distinguished journal published by Elsevier Science Ltd, focusing on the critical fields of cell therapy, transplantation, and regenerative medicine. Since its inception in 1999, the journal has established itself as a vital resource for researchers and practitioners, contributing significantly to advancements in Cancer Research, Cell Biology, Genetics, Immunology, and Oncology. With an impressive range of Q2 rankings across multiple categories and a remarkable Q1 standing in Transplantation for 2023, CYTOTHERAPY delivers high-impact research that addresses the evolving challenges in these fields. While the journal does not offer open access, it remains a reputable avenue for disseminating pivotal studies and reviews that push the boundaries of cell-based therapies. Researchers, clinicians, and students alike will find CYTOTHERAPY an indispensable platform to stay abreast of the latest discoveries and innovations that are shaping the future of medical science.
Cell Stem Cell
Elevating Research Standards in Stem Cell and Molecular BiologyCell Stem Cell, published by CELL PRESS, is a premier journal at the forefront of cellular biology, genetics, and molecular medicine. With an esteemed impact factor and recognized as a Q1 journal in multiple categories including Cell Biology, Genetics, and Molecular Medicine, it offers researchers, professionals, and students rigorous, peer-reviewed articles that shape the future of stem cell research and regenerative medicine. Located in Cambridge, MA, this journal has become an invaluable resource since its inception in 2007 and is committed to disseminating groundbreaking findings that drive innovation and understanding in these critical fields. By consistently ranking within the top percentile of its categories in Scopus, Cell Stem Cell remains an essential platform for scholarly communication, fostering collaboration among leading scientists worldwide. Although the journal does not currently offer open access options, its comprehensive insights are pivotal for anyone engaged in the study of stem cells and their applications.
CURRENT GENE THERAPY
Bridging Research and Clinical Practice.CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.
Tissue Engineering and Regenerative Medicine
Transforming Research into Revolutionary Therapeutic StrategiesTissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.
HUMAN GENE THERAPY
Leading the Charge in Genetic AdvancementsHuman Gene Therapy, an esteemed journal published by Mary Ann Liebert, Inc., is at the forefront of the rapidly evolving fields of genetics, molecular biology, and molecular medicine. With a significant impact in its domain, it is categorized in the Q2 quartile across multiple disciplines, reflecting its commitment to disseminating high-quality, impactful research. Established in 1990, the journal has continuously provided a vital platform for scientists and practitioners to explore groundbreaking developments in gene therapy, genetic engineering, and related technologies. With a focus on peer-reviewed articles that foster advancements in therapeutic applications, Human Gene Therapy serves not only as a comprehensive resource for academia but also as an essential reference for professionals engaged in genetic research and clinical practice. Although currently not open access, the journal remains a crucial source of knowledge, driving innovation and collaboration within the gene therapy community.